Milrinone

Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.

Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.

milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

우리는 고품질의 제품과 경쟁력 있는 가격을 제공할 수 있는 깊은 협력을 바탕으로 많은 고품질 공장을 보유하고 있습니다. 또한 대량 구매 시 할인 혜택도 제공할 수 있습니다. 또한 많은 전문 화물 운송 회사와 협력하여 안전하고 원활하게 제품을 귀하의 손에 전달할 수 있습니다. 배송기간은 결제 확인 후 약 3~20일 정도 소요됩니다.

Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.

1. 당신은 공장입니까 아니면 무역 회사입니까?
우리는 원스톱 서비스를 제공하는 산업과 무역을 통합하는 회사입니다. OEM이 허용될 수 있습니다.

2. 샘플을 제공합니까? 무료인가요 아니면 추가인가요?
무료 샘플. 샘플의 운임은 귀하가 지불해야 합니다.

3. 품질관리 관련 인증서가 있나요?
ISO 9001:2008 인증으로 품질을 보장합니다.

4. 견적을 받으려면 무엇을 제공해야 합니까?
Pls는 귀하가 필요로 하는 제품 유형, 주문 수량, 주소 및 특정 요구 사항을 알려줍니다. 견적은 귀하의 참조를 위해 제 시간에 작성될 것입니다.

5. 어떤 종류의 결제 방식을 선호하시나요? 어떤 종류의 조건이 허용되나요?
허용되는 배송 조건: FOB,CFR,CIF,EXW;
허용되는 결제 통화:USD;
허용되는 지불 유형: T/T, 서부 동맹; 페이팔, 무역 보증.
사용언어:영어.